Timperi Eleonora, Vissio Elena, Marchiò Caterina, Romano Emanuela
INSERM U932, Institut Curie, PSL Research University, Paris, France.
Department of Medical Sciences, University of Turin, Turin, Italy.
Cancer Treat Res. 2020;180:215-249. doi: 10.1007/978-3-030-38862-1_8.
In this chapter, we summarize the latest findings in the field of immuno-oncology of women cancers, particularly ovarian and breast tumors. We describe the relationship between immune parameters and clinical outcomes by evaluating the contribution of different players of the tumor microenvironment, with a particular focus on different immune cell subsets and their essential role during the development of the disease, the response to standard chemotherapy, and to emerging immunotherapeutic approaches. By reviewing the molecular and genetic features of ovarian and breast cancer subtypes, we report on the multitude of factors influencing treatment outcome, with a particular interest on the possible influence of the immune system (i.e., tumor infiltrating lymphocytes, T cells, regulatory T cells, myeloid-derived suppressor cells, dendritic cells, macrophages, B cells, tumor-associated neutrophils). Finally, we discuss emerging immune targets and novel therapeutic modalities that are likely to profoundly influence clinical outcome and prognosis of breast and ovarian cancers in the next future.
在本章中，我们总结了女性癌症免疫肿瘤学领域的最新研究成果，特别是卵巢癌和乳腺癌。我们通过评估肿瘤微环境中不同参与者的作用，描述免疫参数与临床结果之间的关系，特别关注不同的免疫细胞亚群及其在疾病发展、对标准化疗的反应以及新兴免疫治疗方法中的重要作用。通过回顾卵巢癌和乳腺癌亚型的分子和遗传特征，我们报告了影响治疗结果的众多因素，特别关注免疫系统（即肿瘤浸润淋巴细胞、T细胞、调节性T细胞、髓源性抑制细胞、树突状细胞、巨噬细胞、B细胞、肿瘤相关中性粒细胞）的可能影响。最后，我们讨论了新兴的免疫靶点和新的治疗方式，这些可能会在未来深刻影响乳腺癌和卵巢癌的临床结果和预后。
